Completed PHASE4 INTERVENTIONAL 2-arm NCT01673399

Oxytocin Antagonist in Patients With Repeated Failure of Implantation

Oxytocin Antagonist in Patients With Repeated Failure of Implantation. A Prospective Randomized Placebo-controlled Double-blind Study.

Sponsor: AZ Jan Palfijn Gent

Conditions Implantation Failure

Interventions Atosiban placebo

Updated 8 times since 2017 Last updated: Feb 1, 2021 Started: Feb 29, 2012 Primary completion: Feb 28, 2015 Completion: Feb 28, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01673399, this PHASE4 trial focuses on Implantation Failure and remains completed. Sponsored by AZ Jan Palfijn Gent, it has been updated 8 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Mar 2021 — Jul 2024 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Jan 2021 — Mar 2021 [monthly]

Unknown Status PHASE4

▶ Show 3 earlier versions

Apr 2019 — Jan 2021 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jun 2018 — Apr 2019 [monthly]

Recruiting PHASE4
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE4

First recorded

Feb 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AZ Jan Palfijn Gent
Onze Lieve Vrouw Hospital

Data source: AZ Jan Palfijn Gent

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ghent, Belgium